Whittier Trust Co. of Nevada Inc. Purchases 2,432 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Whittier Trust Co. of Nevada Inc. grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 51,614 shares of the medical research company's stock after purchasing an additional 2,432 shares during the period. Whittier Trust Co. of Nevada Inc.'s holdings in IQVIA were worth $10,142,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Avior Wealth Management LLC increased its stake in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock valued at $38,000 after buying an additional 87 shares during the period. Synergy Asset Management LLC acquired a new position in shares of IQVIA during the fourth quarter valued at approximately $33,000. Meeder Asset Management Inc. raised its holdings in IQVIA by 353.7% during the third quarter. Meeder Asset Management Inc. now owns 245 shares of the medical research company's stock worth $58,000 after purchasing an additional 191 shares in the last quarter. Versant Capital Management Inc lifted its position in IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock worth $58,000 after purchasing an additional 93 shares during the period. Finally, SBI Securities Co. Ltd. bought a new position in IQVIA during the 4th quarter valued at $60,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Down 2.7 %

NYSE:IQV traded down $5.04 during mid-day trading on Tuesday, reaching $181.07. The stock had a trading volume of 1,566,007 shares, compared to its average volume of 1,239,209. The business's 50 day moving average is $194.58 and its 200 day moving average is $207.73. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $254.54. The stock has a market cap of $31.93 billion, a P/E ratio of 24.14, a PEG ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

Remove Ads

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Stephens assumed coverage on IQVIA in a report on Friday, December 20th. They issued an "overweight" rating and a $250.00 price objective for the company. Stifel Nicolaus cut their price target on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a report on Friday, February 7th. Bank of America lowered their price objective on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating on the stock in a research note on Friday, December 13th. StockNews.com lowered shares of IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $270.00 price target on shares of IQVIA in a report on Monday, February 10th. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.